ArticleBlood cancer discovery2020
Revealing the impact of structural variants in multiple myeloma.
Open access · greenAbstract read
In one paragraph
Article in Blood cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 2 pooled it
10.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Guideline
- Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data.Scientific reports · 2021Pooled it
- The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance.Molecular diagnosis & therapy · 2026Review
- IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.Blood advances · 2026Article
- Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).Blood · 2026Article
- Genomic Proximity Mapping for Identification of Chromosomal Aberrations in Multiple Myeloma.American journal of hematology · 2026Article
- Micronuclei: origins, assays, mechanisms, diseases and treatments.Signal transduction and targeted therapy · 2026Review
- Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.Nature medicine · 2026Article
- Genomics Define Malignant Transformation in Myeloma Precursor Conditions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.Nature cancer · 2026Article
- Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.Blood cancer discovery · 2025Article
- Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation.Molecular oncology · 2025Article
- Article
- Aging-Related Mechanisms Underlying Carcinogenesis: Therapeutic Opportunities.Aging and disease · 2025Review
- Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.Blood · 2025Article
- Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies.Blood cancer discovery · 2025Article
- Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma.HemaSphere · 2025Article
- Temporal genomic dynamics shape clinical trajectory in multiple myeloma.Nature genetics · 2025Article
- Liquid Biopsy as a Means of Assessing Prognosis and Identifying Novel Risk Factors in Multiple Myeloma.International journal of molecular sciences · 2025Article
- High WEE1 expression is independently linked to poor survival in multiple myeloma.Blood cancer journal · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 13 institutions in 4 countries.
Even H RustadMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9320-4963
Venkata D YellapantulaMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Dominik GlodzikEpidemiology & Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Kylee H MaclachlanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Benjamin DiamondMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8638-9365
Eileen M BoyleNYU Perlmutter Cancer Center, New York, New York.ORCID 0000-0001-8791-1744
Cody AshbyMyeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas.ORCID 0000-0002-9361-0283
Patrick BlaneyNYU Perlmutter Cancer Center, New York, New York.
Gunes GundemEpidemiology & Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Malin HultcrantzMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Daniel LeongamornlertThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.ORCID 0000-0002-3486-3168
Nicos AngelopoulosThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.ORCID 0000-0002-7507-9177
Luca AgnelliDepartment of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Daniel AuclairMultiple Myeloma Research Foundation (MMRF), Norwalk, Connecticut.
Yanming ZhangCytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ahmet DoganHematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Niccolò BolliDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.ORCID 0000-0002-1018-5139
Elli PapaemmanuilEpidemiology & Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Kenneth C AndersonJerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Philippe MoreauCRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
Hervé Avet-LoiseauIUC-Oncopole, and CRCT INSERM U1037, Toulouse, France.
Nikhil C MunshiJerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Jonathan J KeatsTranslational Genomics Research Institute (TGen), Phoenix, Arizona.ORCID 0000-0003-4375-7399
Peter J CampbellThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
Gareth J MorganNYU Perlmutter Cancer Center, New York, New York.ORCID 0000-0002-4271-6360
Ola Landgren *Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Francesco Maura *Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. mauraf@mskcc.org.
Memorial Sloan Kettering Cancer Center · USNYU Langone Health · USWellcome Sanger Institute · GBCentre National de la Recherche Scientifique · FRDana-Farber Cancer Institute · USFondazione IRCCS Istituto Nazionale dei Tumori · ITInserm · FRMultiple Myeloma Research Foundation · USTranslational Genomics Research Institute · USUniversity of Arkansas Medical Center · USUniversity of Essex · GBUniversity of Milan · ITVA Boston Healthcare System · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
The landscape of structural variants (SVs) in multiple myeloma remains poorly understood. Here, we performed comprehensive analysis of SVs in a large cohort of 752 multiple myeloma patients by low coverage long-insert whole genome sequencing. We identified 68 SV hotspots involving 17 new candidate driver genes, including the therapeutic targets BCMA (
Indexed as
ChromothripsisMultiple MyelomaWhole Genome SequencingGenomicsHumansOncogeneschromoplexychromothripsishotspotsmultiple myelomastructural variantstemplated insertion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.